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INTRODUCTION
Phosphorus is an important constituent of nucleotides and is
essential for bone mineralization, muscle function, cellular signal
transduction, and energy storage (1). Serum phosphorus levels
are usually maintained in the normal range of 2.5 mg/dl to 4.5
mg/dl, however, disorders of the kidney decreases phosphorus
excretion in the urine and increases serum phosphorus levels.
It has been reported that an increase in serum phosphorus
levels induces vascular calcification, arterial sclerosis, cardiovas-
cular disease and mortality among renal patients (2-4). It was re-
cently reported that a high phosphorus intake increases serum
phosphorus levels and impairs endothelial function, even in healthy
individuals (5). Therefore, it is advisable that both kidney failure
patients and healthy individuals should avoid having too much
phosphorus. In healthy individuals with normal renal function,
phosphorus homeostasis is tightly controlled by several factors,
such as parathyroid hormone (PTH), fibroblast growth factor 23
(FGF23) and 1,25-dihydroxyvitamin D (1,25(OH)2D) (6-10). These
factors maintain serum phosphorus levels through the control of
renal phosphorus excretion and intestinal phosphorus absorption.
FGF23 is a recently identified molecule, involved in regulating
phosphorus homeostasis (11-13). Secretion of FGF23 is stimu-
lated by an increase in serum phosphorus levels, and principally
acts in the kidney to regulate phosphorus metabolism. FGF23 re-
duces serum phosphorus levels by at least two mechanisms : 1)
it decreases renal phosphorus reabsorption by lowering renal
sodium-phosphorus transporter (NaPi) 2a and NaPi 2c expres-
sion and 2) it decreases intestinal phosphorus absorption by
diminishing plasma 1,25(OH)2D levels which inhibiting 1α -hy-
droxylase and stimulating 24-25hydroxylase activities. It has been
reported that high phosphorus loading increases serum FGF23
levels (6-8). FGF23 is synthesized in osteocytes, and it has been
reported that various factors involved in bone metabolism, such
as phosphate regulating genes with homologies to endopepti-
dases on the X chromosome (PHEX), dentin matrix protein 1
(DMP1), and estrogen, influence its synthesis (14).
Estrogen is one of the factors affecting bone metabolism and
recent studies found that administration of estrogen increased
serum FGF23 levels in ovariectomized rats (15). In the Heart and
Soul Study, serum FGF23 levels were significantly higher in post-
menopausal females compared with males, and were decreased
by estrogen therapy (16). Although some studies have indicated
at an association between serum FGF23 levels and sex, the asso-
ciation has not been fully investigated. It remains unclear whether
secretion of FGF23 in response to dietary phosphorus intake is af-
fected by sex. The purpose of this study was to evaluate whether
sex influences FGF23 responsiveness to dietary phosphorus in-
take in healthy individuals.
MATERIALS AND METHODS
Subjects
Thirty two healthy subjects (14 males and 18 females) between
21 and 28 years were recruited for this study. We performed an-
thropometric measurements and biochemical examinations of
blood to show that subjects had no health problems. The clinical
and biological characteristics of the subjects are shown in Table 1.
All subjects gave written informed consent and the ethical com-
mittee of the University of Shizuoka approved this study. The pro-
tocol conformed to the Helsinki Declaration.
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Protocol
This study was implemented according to a previously published
method (17). Subjects performed 24-hour urine collection and
weighed dietary records. Subjects were asked to avoid participa-
tion in heavy exercise during the study. Subjects weren’t limited
in any other activities or dietary intake and were prescribed to
spend a day as normal. On the following morning, dietary records,
pictures of foods consumed and 24-hour urine samples were col-
lected, in addition, blood was taken after sufficient rest. Subjects
participated three times in these exams with at least one day in-
tervals.
24-hour urine collection method
Subjects performed the 24-hour urine collection method using
URIN-MATEP (Sumitomo Chemical Co. Ltd., Tokyo, Japan), which
could accumulate 1/50th of whole urine, over a 24-hour monitor-
ing period. Subjects were instructed to discard the first morning
void and to collect all urine over the following 24-hours, including
the first void on the next morning. After weighing the total volume
of urine from each individual, samples were dispensed them into
vessels for storage at 4 or -30 until use. The analysis company,
SRL Inc, (Tokyo, Japan) measured urine nitrogen levels, creatinine
levels and inorganic phosphorus levels. Weighed dietary records
often over- or underestimate phosphorus intake because it does
not add phosphorus derived from food additive, fluctuations in
phosphorus content due to cooking loss and production region
and picking seasons are not considered. We reported that the 24-
hour urine collection method can estimate the amount of dietary
phosphorus intake, and were superior to estimation by weighed
dietary record (17). So, we calculated the daily dietary intake,
estimated from the urine collection (UC), of phosphorus (UC-P).
We calculated UC-P based on a report that phosphorus absorption
was about 65% (17).
UC-P (mg/day)=urine phosphorus excretion (mg/day)/0.65

Anthropometric and biochemical examinations of blood
Height, body weight, body fat percentage and lean body mass
were calculated using a bioelectrical impedance analysis method
(TANITA TBF-215 ; TANITA Corporation, Tokyo, Japan). Body
Mass Index (BMI) was calculated using the following formula :
BMI=body weight (kg)/body height (m)2
Blood samples were dispensed into vacuum blood collection
tubes and centrifuged (4, 3000 rpm, 10 min) immediately. Serum
and plasma samples were separated and stored at -30 until use.
Triglyceride (TG), low-density lipoprotein cholesterol (LDL-
Cho), high-density lipoprotein cholesterol (HDL-Cho), hemoglo-
bin A1c (HbA1c), total protein (TP), albumin (Alb), urea nitrogen
(UN), creatinine (Cre), sodium (Na), potassium (K), chloride (Cl),
calcium (Ca), phosphorus (Pi), intact parathyroid hormone (PTH)
and intact FGF23 (FGF23) levels were measured by SRL Inc.
Statistical analysis
Data were described as meansSD. The data were tested for
normality using the Shapiro-Wilk test. All statistical analyses were
performed with SPSS Statistic, version 19.0 for Windows (1989-
2010, SPSS, Inc., an IBM Company, US) and were considered sta-
tistically significant at P0.05. Pearson’s correlation coefficient
was used to evaluate association between UC-P and serum FGF23
levels. Two-sample t- tests and Mann-Whitney tests were used to
compare serum FGF23 levels, serum FGF23 levels/UC-P and
serum FGF23 levels/UC-P/BW between the male and female
groups.
Table 1. Characteristics of the subjects and sex comparison.
Total
(n=32)
Male
(n=14)
Female
(n=18) P value
Age (year) 22.8  2.0 22.8  2.0 21.5  0.7
HT (cm) 164.4  9.6 172.5  6.7 158.1  6.0 0.01
BW (kg) 57.3  10.8 65.7  10.8 50.8  4.7 0.01
BFP (%) 21.4  5.8 18.6  4.9 24.3  4.7 0.01
LBM (kg) 44.5  9.2 53.1  6.7 37.7  3.6 0.01
BMI (kg/m2) 21.1  2.7 22.0  2.7 20.4  2.5 0.11
TG (mg/dL) 62.3  29.7 72.4  35.4 54.5  22.4 0.16
LDL-c (mg/dL) 93.3  24.2 87.0  26.4 98.2  21.8 0.20
HDL-c (mg/dL) 63.4  12.4 58.3  8.2 63.4  12.4 0.05
HbA1c (%) 4.9  0.2 4.9  0.2 5.0  0.2 0.38
TP (g/dL) 7.4  0.4 7.4  0.5 7.5  0.4 0.52
Alb (g/dL) 4.8  0.3 4.8  0.3 4.7  0.3 0.70
UN (mg/dL) 12.8  2.8 13.3  3.2 12.4  2.5 0.34
Cre (mg/dL) 0.73  0.14 0.86  0.09 0.63  0.06 0.01
Na (mEq/L) 140.7  1.4 140.9  1.4 140.5  1.3 0.28
K (mEq/L) 4.2  0.3 4.1  0.3 4.2  0.3 0.46
Cl (mEq/L) 104.4  1.5 104  1.4 104.7  1.4 0.17
Ca (mg/dL) 9.5  0.3 9.6  0.3 9.5  0.2 0.20
Pi (mg/dL) 4.0  0.4 3.7  0.5 4.2  0.3 0.01
PTH (pg/mL) 42.8  12.4 44.9  14.1 41.2  2.6 0.41
Data are meansSD.
HT, height ; BW, body weight ; BFP, body fat percentage ; LBM, lean body mass ; BMI, body mass index ; TG, triglyceride ; LDL-c, low density
lipoprotein -cholesterol ; HDL-c, high density lipoprotein -cholesterol ; HbA1c, hemoglobinA1c ; TP, total protein ; Alb, albumin ; UN, urea nitro-
gen ; Cre, creatinine ; Na, sodium ; K, potassium ; Cl, chlorine ; Ca, calcium ; Pi, phosphorus ; PTH, intact parathyroid hormone.
Two sample t - test or Mann-Whitney test was used for compare male and female.
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RESULTS
Subject characteristics
The characteristics of the subjects are shown in Table 1. Mean
age was 22.11.5 years and body mass index was 21.02.7 kg/m2.
Subjects had normal glucose and lipid metabolism, hepatic func-
tion and renal function.
The association between UC-P and serum FGF23 levels
Positive correlation was observed between UC-P and serum
FGF23 levels (r=0.35 ; P0.01) (Figure 1).
Serum FGF23 levels comparisons between males and females
To evaluate whether sex could influence FGF23 responsive-
ness to dietary phosphorus intake, serum FGF23 levels were com-
pared between male and female subjects (Figure 2). Serum FGF23
levels were significantly higher in males than in females (37.48.2
pg/ml and 33.17.5 pg/ml, respectively) (P0.05) (Figure 2a).
UC-P was also significantly higher in males compared to females
(1141308 mg/day and 788264 mg/day, respectively) (P0.01)
(Figure 2b). However, serum FGF23 levels/UC-P was significantly
higher in females than in males (P0.01). Serum levels/UC-P in
males was 0.0350.012 pg/ml and in females was 0.0470.025
pg/ml (Figure 2c). UC-P/BW was significantly higher in males
than in females (17.44.3 mg/kg and 15.64.9 mg/kg, respec-
tively) (P0.05) (Figure 2d). To examine the effect of UC-P/BW
on serum FGF23 levels, we analyzed sex differences in serum
FGF23 levels/UC-P/BW. There was no significant difference in
serum FGF23 levels/UC-P/BW between males and females (2.3
0.7 pg/ml and 2.41.5 pg/ml, respectively) (P=0.95) (Figure 2e).
DISCUSSION
This study evaluated whether sex influenced FGF23 responsive-
ness to dietary phosphorus intake. UC-P and serum FGF23 levels
were positively associated. FGF23 contributed to phosphorus ho-
meostasis through suppression of renal phosphorus reabsorption
and intestinal phosphorus absorption (18, 19). In a previous study,
using a phosphorus loading test with three test meals containing
different phosphorus levels (400 mg/meal : P400, 800 mg/meal :
P800, and 1200 mg/meal : P1200), serum FGF23 levels were little
changed after P400 and P800 loading, but significantly increased
at 8 h after P1200 loading (6). Another study reported that serum
FGF23 levels were significantly higher after 2500 mg phosphorus
Figure 1. Univariate association between UC-P and serum FGF23
levels.
Pearson’s product moment correlation coefficient (r) and its P value are
represented. Closed circle : male ; open square : female. UC : estimated
intake calculated by 24-hour urine collection.
Figure2. Sex comparison of serum FGF23 levels.
Serum FGF23 levels (a), UC-P (b), serum FGF23 levels/UC-P (c), UC-P/BW (d), serum FGF23 levels/UC-P/BW (e). *P0.05 : male vs female
by two-sample t - test. **P0.01 : male vs female by two-sample t - test. P0.05 : male vs female by Mann-Whitney test. P0.01 : male vs female
by Mann-Whitney test.
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loading than after 500 mg phosphorus loading (20). Therefore,
the association between UC-P and serum FGF23 levels observed
in this study suggests that FGF23 was secreted in response to the
amount of phosphorus ingested in order to maintain phosphorus
homeostasis, however, the correlation was weak (r=0.35 ; P
0.01). We previously reported that the 24-hour urine collection
method could be used to estimate diurnal dietary phosphorus in-
take (17). It is considered that serum FGF23 levels might be af-
fected by prolonged phosphorus intake, PTH (21), 1,25(OH)2D
(21) and genetic factor such as single nucleotide polymorphism
(22, 23), which might be one of the reasons for a weak association
between UC-P and serum FGF23 levels. In this study, associations
between serum FGF23 levels and these factors were not investi-
gated, so we needed to investigate these associations in the future
study.
We compared UC-P and serum FGF23 levels between male and
female subjects to evaluate whether sex could influence FGF23 re-
sponsiveness to dietary phosphorus intake. Serum FGF23 levels
were significantly higher in males compared to females. However,
serum FGF23 levels/UC-P was significantly higher in females
than in males. There was no significant difference in serum FGF23
levels/UC-P/BW between male and female subjects. Male sub-
jects had significantly higher UC-P/BW compared with females.
These results suggest that there is no difference in FGF23 respon-
siveness to phosphorus intake per body weight between males
and females, but UC-P/BW in males was higher than in females
and as a result, serum FGF23 levels was significantly higher in
males. The recommended intake amounts of phosphorus are 1000
mg/day for adult males and 900 mg/day for adult females, and
the tolerable upper limit of phosphorus intake is 3000 mg/day for
both adult males and females in Japan (24). The results of this
study suggest that recommended intake and tolerable upper limit
of phosphorus intake needs to be established according to body
weight.
A previous study reported that serum FGF23 levels in post-
menopausal females were significantly higher than in males, and
were decreased by estrogen therapy (16). Since the estrogen re-
ceptor is present at the proximal tubule which regulates urinary
phosphorus excretion, it has been suggested that serum phospho-
rus levels are increased by hormonal imbalance with menopause,
and FGF23 secretion is increased. A previous study suggested
that serum phosphorus levels are higher in postmenopausal fe-
males compared with menstruating females (25). It is also reported
that postmenopausal status is associated with higher serum phos-
phorus levels (26). The female subjects in this study were premeno-
pausal, suggesting there would be no difference in serum FGF23
levels/UC-P/BW between male and female subjects, however,
estrogen was not measured in this study and it is unclear whether
estrogen influenced FGF23 responsiveness to phosphorus intake.
Phosphorus intake and serum FGF23 levels correlated in all sub-
jects in this study however, the correlation was weaker in female
subjects (data not shown). There are two possible reasons for these
results : the female subjects in this study may have paid more at-
tention to their diet and body habitus compared to male subjects
(27). The variation in body weight, body fat mass and lean body
mass of the female subjects were smaller when compared with the
male subjects. Phosphorus intake in females was significantly lower
than that in males, and there was no difference in variation in data.
Recently, it has been shown that leptin stimulates FGF23 produc-
tion in bone (28). Plasma leptin levels are increased in obesity, and
are strongly associated with body fat mass (29). Administration of
intraperitoneal leptin in ob/ob mice increased FGF23 mRNA in
the bones and serum FGF23 levels (28) and serum leptin levels
were significantly higher in a human study group with high se-
rum FGF23 levels compared with a low serum FGF23 level study
group (30). It has also been reported that serum FGF23 levels are
associated with body fat mass and percent body fat. In our study,
the female subject’s body fat was distributed in a narrow range,
so association between phosphorus intake and serum FGF23 lev-
els was found to be weaker in female subjects compared with male
subjects. The second reason for the weaker correlation is that the
estradiol cycle (menstrual cycle) may influence FGF23 secretion.
In this study, test days were selected to fall outside the menstrual
periods of the female subjects, but we did not adjust for phase of
menstrual cycle. The difference in menstrual cycle phase among
individual females might effect FGF23 secretion. Further studies
on menstrual cycle and serum estrogen levels are required to re-
veal whether sex could influence FGF23 responsiveness to phos-
phorus intake.
Our results indicate that sex had no effect on FGF23 responsive-
ness to phosphorus intake per body weight. Though recommended
intake amounts of phosphorus are uniformly established, our re-
sults suggest that it should be recalculated on the basis of body
weight. Further studies examining the influence of sex and physi-
cal constitution on FGF23 responsiveness to dietary phosphorus
intake are needed to establish recommended intake amounts of
phosphorus.
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